Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Mary Ann Liebert's peer-reviewed journal highlights latest developments in ocular gene therapy

Mary Ann Liebert's peer-reviewed journal highlights latest developments in ocular gene therapy

Retina Implant's second clinical trial initial findings presented at ARVO 2011

Retina Implant's second clinical trial initial findings presented at ARVO 2011

Researchers report game-changing advance in stem cell science

Researchers report game-changing advance in stem cell science

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

New discovery may improve cochlear implants for deafness

New discovery may improve cochlear implants for deafness

SMR, RTU enter license agreement for RESCULA eye drops

SMR, RTU enter license agreement for RESCULA eye drops

Retina Implant to join with Wills Eye for U.S. artificial vision clinical trial

Retina Implant to join with Wills Eye for U.S. artificial vision clinical trial

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT fourth quarter revenues decrease 7.3% to $10.0 million

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

UM researchers find genetic cause of retinitis pigmentosa

UM researchers find genetic cause of retinitis pigmentosa

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

NEI awards Case Western Reserve $10M for study of retinal diseases

NEI awards Case Western Reserve $10M for study of retinal diseases

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

Stem cell trial for eye disease receives FDA approval

Stem cell trial for eye disease receives FDA approval

Multinational team identifies novel retinal disease gene

Multinational team identifies novel retinal disease gene

Eye implant restores some vision in retinitis pigmentosa

Eye implant restores some vision in retinitis pigmentosa

QLT third quarter sales decreases 12.9% to $20.5 million

QLT third quarter sales decreases 12.9% to $20.5 million

Retina Implant's microchip restores useful vision in patients blind due to retinitis pigmentosa

Retina Implant's microchip restores useful vision in patients blind due to retinitis pigmentosa